Broadly neutralizing antibodies suppress post-transcytosis HIV-1 infectivity

Mucosal Immunol. 2017 May;10(3):814-826. doi: 10.1038/mi.2016.106. Epub 2016 Dec 14.

Abstract

Broadly neutralizing antibodies (bNAbs) offer promising opportunities for preventing HIV-1 infection in humans. Immunoprophylaxis with potent bNAbs efficiently protects non-human primates from mucosal transmission even after repeated challenges. However, the precise mechanisms of bNAb-mediated viral inhibition in mucosal tissues are currently unknown. Here, we show that immunoglobulin (Ig)G and IgA bNAbs do not interfere with the endocytic transport of HIV-1 across epithelial cells, a process referred to as transcytosis. Instead, both viruses and antibodies are translocated to the basal pole of epithelial cells, possibly in the form of an immune complex. Importantly, as opposed to free virions, viral particles bound by bNAbs are no longer infectious after transepithelial transit. Post-transcytosis neutralization activity of bNAbs displays comparable inhibitory concentrations as those measured in classical neutralization assays. Thus, bNAbs do not block the transport of incoming HIV-1 viruses across the mucosal epithelium but rather neutralize the transcytosed virions, highlighting their efficient prophylactic and protective activity in vivo.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • AIDS Vaccines / immunology*
  • Animals
  • Antibodies, Neutralizing / immunology*
  • Cells, Cultured
  • Cross Reactions
  • Epithelial Cells / immunology*
  • Epithelial Cells / virology
  • HIV Antibodies / immunology*
  • HIV Antigens / immunology
  • HIV Infections / immunology*
  • HIV-1 / pathogenicity
  • HIV-1 / physiology*
  • Humans
  • Immunoglobulin A / immunology
  • Immunoglobulin G / immunology
  • Primates
  • Transcytosis
  • Virion / metabolism*
  • Virulence

Substances

  • AIDS Vaccines
  • Antibodies, Neutralizing
  • HIV Antibodies
  • HIV Antigens
  • Immunoglobulin A
  • Immunoglobulin G